AIM

AIM ImmunoTech Inc

0.1800

Oct 09 • 3:59 PM ET +0.0004 (0.22%)

0.1800

Aftermarket • 7:44 PM ET 0.0000 (0.00%)

Healthcare Biotechnology USA Nano AMEX

Peers: APRE BCDA BIVI GOVX KAPA KPRX LNAI CALC CVM NEUP

Scroll to Statements

Index	-
Market Cap	7.18M
Enterprise Value	1.14M
Income	-14.27M
Sales	0.10M
Book/sh	0.27
Cash/sh	0.25
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	19
IPO	Jul 15, 1996

P/E	-
Forward P/E	-
PEG	-
P/S	71.80
P/B	0.67
P/C	0.72
P/FCF	-
EV/EBITDA	-
EV/Sales	11.40
Quick Ratio	2.11
Current Ratio	2.11
Debt/Eq	0.51
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-3.84
EPS next Y	-0.54
EPS next Q	-0.14
EPS this Y	90.02%
EPS next Y	37.21%
EPS next 5Y	58.64%
EPS past 3/5Y	40.27% 28.21%
Sales past 3/5Y	-14.54% -11.60%
EPS Y/Y TTM	84.62%
Sales Y/Y TTM	-21.49%
EPS Q/Q	93.98%
Sales Q/Q	4.00%
Earnings	Aug 10 BMO
EPS/Sales Surpr.	-152.94% -

Insider Own	0.52%
Insider Trans	43.52%
Inst Own	2.88%
Inst Trans	2.95%
ROA	-169.28%
ROE	-2382.30%
ROIC	-183.30%
Gross Margin	-726.32%
Oper. Margin	-11148.42%
Profit Margin	-15021.05%
SMA20	-8.10%
SMA50	-20.73%
SMA200	-68.58%
Trades

Shs Outstand	39.89M
Shs Float	39.69M
Short Float	3.55%
Short Ratio	0.30
Short Interest	1.41M
52W High	2.88 -93.74%
52W Low	0.17 8.50%
Volatility	4.65% 5.72%
ATR (14)	0.01
RSI (14)	36.28
Beta	1.32
Rel Volume	0.09
Avg Volume	4.64M
Volume	424,182

Perf Week	0.00%
Perf Month	-20.67%
Perf Quarter	-32.33%
Perf Half Y	-65.65%
Perf YTD	-84.05%
Perf Year	-93.10%
Perf 3Y	-99.62%
Perf 5Y	-99.90%
Perf 10Y	-100.00%
Recom	1.00
Target Price	4.25
Prev Close	0.18
Price	0.18
Change %	0.22%

Oct-07-26 09:14AM	AIM ImmunoTech's Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays (GlobeNewswire)
Oct-05-26 09:22AM	AIM ImmunoTech Highlights Recent Media Coverage of Ampligen's Broad-Spectrum Antiviral and Biodefense Potential (GlobeNewswire) +5.56%
Oct-01-26 09:02AM	AIM ImmunoTech Spotlights Growing Attention Around Ampligen Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data (GlobeNewswire) +7.26%
Sep-30-26 08:44AM	AIM ImmunoTech Discusses Ampligen's Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video (GlobeNewswire)
Sep-22-26 08:55AM	AIM ImmunoTech Highlights Ampligen's Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines' Daraxonrasib (GlobeNewswire)
09:03AM	Loading…
Sep-09-26 09:03AM	AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen in Pancreatic Cancer in New CEO Corner Video (GlobeNewswire)
Sep-02-26 08:43AM	AIM ImmunoTech Significantly Expands Ampligen Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041 (GlobeNewswire)
Aug-31-26 08:51AM	AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen) Used in Combination with Pembrolizumab (Keytruda), Expanding Oncology IP Protection for Ampligen Through 2039 (GlobeNewswire) -12.54%
Aug-27-26 09:01AM	AIM ImmunoTech Participates in the Virtual Investor 'Why Now' On-Demand Conference (GlobeNewswire)
Aug-12-26 08:44AM	AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published 'Breaking Defense' Article (GlobeNewswire)
Aug-10-26 08:36AM	AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen Toward Planned Phase 3 Development in Pancreatic Cancer (GlobeNewswire) -7.85%
Aug-03-26 08:33AM	AIM ImmunoTech Ahead of Schedule on 'Last Dose' DURIPANC Critical Clinical Inflection Point (GlobeNewswire)
Jul-07-26 09:03AM	AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program (GlobeNewswire)
Jun-24-26 08:29AM	AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones (GlobeNewswire)
Jun-22-26 08:45AM	AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series (GlobeNewswire)
09:01AM	Loading…
Jun-18-26 09:01AM	AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer (GlobeNewswire) -5.02%
Jun-15-26 08:01AM	AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency (GlobeNewswire)
Jun-09-26 09:29AM	AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules (GlobeNewswire) -22.34%
Jun-08-26 08:33AM	AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer (GlobeNewswire)
Jun-04-26 08:55AM	AIM ImmunoTech Releases Virtual Investor 'What This Means' Video Segment Discussing Ampligen's Potential in Ebola Virus Disease Preparedness (GlobeNewswire) -19.22%
Jun-01-26 10:19AM	AIM Stock Soars Over 200% As Pancreatic Cancer Trial Hits Enrollment Milestone Early CEO Sees 'Value-Inflection Period' Ahead (Stocktwits) +120.35%
10:19AM	AIM Stock Soars 42% As Pancreatic Cancer Trial Hits Key Enrollment Milestone Before Schedule CEO Sees 'Significant Value-Inflection Period' Ahead (Stocktwits)
08:58AM	AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones (GlobeNewswire)
May-27-26 08:47AM	AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration (GlobeNewswire) +72.37%
May-20-26 03:02PM	AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement (GlobeNewswire) -38.42%
May-19-26 08:02AM	AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities (GlobeNewswire)
May-14-26 08:41AM	AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer (GlobeNewswire)
May-08-26 08:40AM	AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds (GlobeNewswire) -39.66%
May-07-26 08:23AM	AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential (GlobeNewswire) +16.42%
Apr-16-26 09:00AM	AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP (GlobeNewswire)
06:00PM	Loading…
Apr-13-26 06:00PM	AIM ImmunoTech Provides Routine Update on Annual Filings (GlobeNewswire) +8.95%
Apr-09-26 08:00AM	AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event (GlobeNewswire) -6.24%
Mar-18-26 08:36AM	AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors (GlobeNewswire) +43.66%
Mar-06-26 07:00PM	AIM ImmunoTech Announces Closing of its Rights Offering (GlobeNewswire) +8.33%
Mar-04-26 09:00AM	AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million (GlobeNewswire)
Mar-02-26 09:00AM	AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer (GlobeNewswire) -14.89%
Feb-27-26 09:00AM	AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering (GlobeNewswire) -8.32%
Feb-25-26 09:00AM	AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026 (GlobeNewswire)
Feb-23-26 08:55AM	AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer (GlobeNewswire)
Feb-12-26 04:35PM	CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering (GlobeNewswire) -6.36% +58.23%
08:55AM	AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event (GlobeNewswire)
Feb-11-26 08:30AM	AIM ImmunoTech Announces Commencement of Rights Offering (GlobeNewswire) -13.51%
Feb-06-26 08:55AM	AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial (GlobeNewswire) -7.32%
Feb-05-26 08:40AM	AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer (GlobeNewswire) +16.59%
Jan-28-26 09:40AM	Are Medical Stocks Lagging AIM ImmunoTech (AIM) This Year? (Zacks)
Jan-27-26 04:35PM	AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering (GlobeNewswire)
Jan-23-26 01:22PM	AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering (GlobeNewswire) -5.16%
Jan-08-26 09:40AM	Is AIM ImmunoTech (AIM) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-30-25 05:10PM	AIM ImmunoTech Announces Stock Dividend (GlobeNewswire) -10.32%
Dec-16-25 01:17PM	Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B (PR Newswire)
Dec-10-25 09:00AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire)
Dec-01-25 08:55AM	AIM ImmunoTech to Participate in Live 'Fireside' Chat on Virtual Investor Closing Bell Series (GlobeNewswire)
Nov-18-25 08:55AM	AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program (GlobeNewswire) -7.64%
Nov-10-25 08:55AM	AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer (GlobeNewswire) -6.37%
Nov-04-25 09:05AM	AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting (GlobeNewswire) -20.40%
Nov-03-25 08:55AM	AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue (GlobeNewswire)
Oct-23-25 08:51AM	Zacks.com featured highlights include The Honest Company, Dutch, AIM ImmunoTech, Masimo and Cognizant Technology Solutions (Zacks)
Oct-22-25 12:02PM	Bet On 5 Top-Ranked Stocks With Rising P/E (Zacks)
Oct-20-25 09:15AM	AIM ImmunoTech to Attend the 2025 Maxim Growth Summit (GlobeNewswire)
Oct-10-25 12:00PM	All You Need to Know About AIM ImmunoTech (AIM) Rating Upgrade to Buy (Zacks)
Sep-25-25 08:45AM	AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen (Rintatolimod) with Checkpoint Inhibitors (GlobeNewswire)
Sep-22-25 09:00AM	AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth (GlobeNewswire) +6.16%
Sep-21-25 09:10AM	Maxim Group Sees 133% Upside in AIM ImmunoTech Inc. (AIM) (Insider Monkey)
Sep-04-25 11:00AM	AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland (GlobeNewswire)
Aug-21-25 09:00AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire) +8.47%
Aug-15-25 09:00AM	AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-14-25 08:55AM	AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech (GlobeNewswire)
Aug-11-25 06:55PM	FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-06-25 09:00AM	AIM ImmunoTechs Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025) (GlobeNewswire)
09:00AM	AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025) (GlobeNewswire)
Aug-04-25 09:00AM	AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen Clinical Development Toward Pancreatic Cancer Approval (GlobeNewswire) +6.36%
Jul-31-25 09:00AM	AIM ImmunoTech Announces Closing of $8.0 Million Public Offering (GlobeNewswire)
Jul-29-25 09:00AM	AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering (GlobeNewswire) -56.25%
Jul-28-25 09:00AM	AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer (GlobeNewswire) -14.29%
Jul-02-25 08:55AM	AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies (GlobeNewswire)
Jun-20-25 04:15PM	AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements (GlobeNewswire) +10.96%
Jun-17-25 08:55AM	AIM ImmunoTech Resumes Trading on NYSE American (GlobeNewswire) +6.84%
Apr-07-25 01:26PM	AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market (GlobeNewswire) -57.53%
Apr-04-25 04:45PM	AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal (GlobeNewswire) -19.37%
Mar-27-25 08:05AM	AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

J.D.Mr. Thomas K. Equels Esq.

B.A.Mr. Robert Dickey IV

Esq.Mr. Peter W. Rodino III

Director of Administration & Human Resources and Deputy Investor Relations CoordinatorAnn Marie E. Coverly

M.D.Dr. Christopher Nicodemus FACP

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Equels Thomas K	CEO & President	Sep 17 '26	Buy	0.21	24,000	4,992	126,822	Sep 18 08:30 AM
Equels Thomas K	CEO & President	Sep 16 '26	Buy	0.21	11,000	2,310	102,822	Sep 17 12:01 PM
Equels Thomas K	CEO & President	Sep 15 '26	Buy	0.22	22,000	4,862	91,822	Sep 16 09:15 AM
Equels Thomas K	CEO & President	Sep 14 '26	Buy	0.22	5,900	1,292	69,822	Sep 15 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AIM

AIM ImmunoTech Inc

Upgrade your Finviz experience